436 related articles for article (PubMed ID: 25171848)
21. Using motivational interviewing in the community pharmacy to increase adult immunization readiness: A pilot evaluation.
Brackett A; Butler M; Chapman L
J Am Pharm Assoc (2003); 2015; 55(2):182-6. PubMed ID: 25615903
[TBL] [Abstract][Full Text] [Related]
22. Vaccination against zoster remains effective in older adults who later undergo chemotherapy.
Tseng HF; Tartof S; Harpaz R; Luo Y; Sy LS; Hetcher RC; Jacobsen SJ
Clin Infect Dis; 2014 Oct; 59(7):913-9. PubMed ID: 25097079
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the acceptability of a vaccine against herpes zoster in the over 50 years old: an Italian observational study.
Valente N; Lupi S; Stefanati A; Cova M; Sulcaj N; Piccinni L; ; Gabutti G
BMJ Open; 2016 Oct; 6(10):e011539. PubMed ID: 27797989
[TBL] [Abstract][Full Text] [Related]
24. Improvement in Herpes Zoster Vaccination in Patients with Rheumatoid Arthritis: A Quality Improvement Project.
Sheth H; Moreland L; Peterson H; Aggarwal R
J Rheumatol; 2017 Jan; 44(1):11-17. PubMed ID: 28042124
[TBL] [Abstract][Full Text] [Related]
25. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
[TBL] [Abstract][Full Text] [Related]
26. Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster.
Sly JR; Harris AL
Nurs Womens Health; 2018 Oct; 22(5):417-422. PubMed ID: 30145235
[TBL] [Abstract][Full Text] [Related]
27. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.
Zhang J; Delzell E; Xie F; Baddley JW; Spettell C; McMahan RM; Fernandes J; Chen L; Winthrop K; Curtis JR
Arthritis Res Ther; 2011; 13(5):R174. PubMed ID: 22024532
[TBL] [Abstract][Full Text] [Related]
28. Evaluating Physician Attitudes and Practices Regarding Herpes Zoster Vaccination.
Tsui E; Gillespie C; Perskin M; Zabar S; Wu M; Cohen EJ
Cornea; 2018 Aug; 37(8):947-951. PubMed ID: 29578865
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?
Safonova E; Yawn BP; Welte T; Wang C
Respir Res; 2023 Jan; 24(1):35. PubMed ID: 36709298
[TBL] [Abstract][Full Text] [Related]
30. Differential uptake of herpes zoster vaccination associated with socioeconomic status: A population-based study in Stockholm County, Sweden.
Fogelberg S; Lamb F; Grönlund O; Eriksson I; Sundström K; Clements M; Arnheim-Dahlström L
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1159-1165. PubMed ID: 30221421
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
Vesikari T; Hardt R; Rümke HC; Icardi G; Montero J; Thomas S; Sadorge C; Fiquet A
Hum Vaccin Immunother; 2013 Apr; 9(4):858-64. PubMed ID: 23319176
[TBL] [Abstract][Full Text] [Related]
32. When zoster hits close to home: Impact of personal zoster awareness on zoster vaccine uptake in the U.S.
Harpaz R; Leung J
Vaccine; 2017 Jun; 35(27):3457-3460. PubMed ID: 28528766
[TBL] [Abstract][Full Text] [Related]
33. The impact of an immunization check-up at a pharmacist-provided employee health screening.
Sparkman A; Brookhart AL; Goode JKR
J Am Pharm Assoc (2003); 2017; 57(3S):S274-S278. PubMed ID: 28366600
[TBL] [Abstract][Full Text] [Related]
34. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
Yao CA; Chen LK; Huang KC
Vaccine; 2015 Mar; 33(13):1515-7. PubMed ID: 25681662
[TBL] [Abstract][Full Text] [Related]
35. Pharmacist-led Tdap vaccination of close contacts of neonates in a women's hospital.
Mills B; Fensterheim L; Taitel M; Cannon A
Vaccine; 2014 Jan; 32(4):521-5. PubMed ID: 24269619
[TBL] [Abstract][Full Text] [Related]
36. Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of age.
Li X; Zhang JH; Betts RF; Morrison VA; Xu R; Itzler RF; Acosta CJ; Dasbach EJ; Pellissier JM; Johnson GR; Chan IS
Vaccine; 2015 Mar; 33(12):1499-505. PubMed ID: 25444784
[TBL] [Abstract][Full Text] [Related]
37. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(44):1528. PubMed ID: 22071592
[TBL] [Abstract][Full Text] [Related]
38. Survey of Australian inpatients on vaccination status and perceptions of influenza vaccination.
Loke XY; Tran W; Alderman CP
Consult Pharm; 2012 Aug; 27(8):553-63. PubMed ID: 22910176
[TBL] [Abstract][Full Text] [Related]
39. Shingrix for Herpes Zoster: A Review.
Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK
Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with shingles and pneumococcal vaccination among older Canadians.
Gilmour H
Health Rep; 2024 Jan; 35(1):14-24. PubMed ID: 38232409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
